Jefferies Group's KALV Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 286,046 shares of KalVista Pharmaceuticals, Inc. (KALV) worth $5.76 M, representing 0.04% of the portfolio. First purchased in 2022-Q4, this medium-term investment has been held for 14 quarters.
Based on 13F filings, Jefferies Group has maintained a strategic position in KALV, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 286,875 shares. Largest reduction occurred in Q1 2024, reducing 1.04 M shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's KalVista Pharmaceuticals (KALV) Holding Value Over Time
Track share changes against reported price movement
Quarterly KalVista Pharmaceuticals (KALV) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +286,046 | New Buy | 286,046 | $20.13 |
| Q4 2025 | -286,875 | Sold Out | 0 | $0.00 |
| Q3 2025 | +286,875 | New Buy | 286,875 | $12.18 |
| Q2 2025 | -375,000 | Sold Out | 0 | $0.00 |
| Q3 2024 | +200,000 | Add 114.29% | 375,000 | $11.58 |
| Q2 2024 | +140,000 | Add 400.00% | 175,000 | $11.78 |
| Q1 2024 | -1.04 M | Reduce 96.76% | 35,000 | $11.86 |
| Q4 2023 | +50,000 | Add 4.85% | 1.08 M | $12.25 |
| Q2 2023 | -170,000 | Reduce 14.17% | 1.03 M | $9.00 |
| Q4 2022 | +1.2 M | New Buy | 1.2 M | $6.76 |
Jefferies Group's KalVista Pharmaceuticals Investment FAQs
Jefferies Group first purchased KalVista Pharmaceuticals, Inc. (KALV) in Q4 2022, acquiring 1,200,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held KalVista Pharmaceuticals, Inc. (KALV) for 14 quarters since Q4 2022.
Jefferies Group's largest addition to KalVista Pharmaceuticals, Inc. (KALV) was in Q4 2022, adding 1,200,000 shares worth $8.11 M.
According to the latest 13F filing for Q1 2026, Jefferies Group's firm, Jefferies Financial Group Inc., owns 286,046 shares of KalVista Pharmaceuticals, Inc. (KALV), valued at approximately $5.76 M.
As of the Q1 2026 filing, KalVista Pharmaceuticals, Inc. (KALV) represents approximately 0.04% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in KalVista Pharmaceuticals, Inc. (KALV) was 1,200,000 shares, as reported at the end of Q4 2022.